Charcot-Marie-Tooth disease type 4B (CMT4B) is a demyelinating autosomal recessive motor and sensory neuropathy characterised by focally folded myelin sheaths in the peripheral nerve. The CMT4B gene has been localised by homozygosity mapping and haplotype sharing in the 11q23 region. A cDNA encoding for the 2 subunit of the human brain sodium channel, SCN2B, has been recently assigned to the same chromosomal interval by FISH. The SCN2B gene has been considered a good candidate for CMT4B on the basis of protein homology, chromosomal localisation, and putative biological function of the coded product. In this paper, we report the genomic structure of the SCN2B gene consisting of 4 exons and 3 introns spanning a region of approximately 12 Kb. In addition, a search for mutations in patients affected with CMT4B as well as a refined physical localisation excludes SCN2B as the CMT4B gene.
Introduction
Among the heterogeneous group of the autosomal recessive demyelinating hereditary motor and sensory neuropathies (HMSN) three pathological forms are now recognised, one with classical onion bulbs, one with basal lamina onion bulbs or Charcot-Marie-Tooth (CMT) type 4A, 1 and a third characterised by focally folded myelin sheaths or Charcot-Marie-Tooth type 4B (CMT4B). 2 We previously reported a large inbred pedigree with recurrence of demyelinating motor and sensory neuropathy with focally folded myelin sheaths, CMT4B, inherited as an autosomal recessive trait. 3 Taking advantage of the particular inbred structure of the family, we used homozygosity mapping and haplotype sharing to localise, through a genome-wide search, the CMT4B gene on chromosome 11q23 in a 5 cM interval between D11S1332 and D11S917. 4 Recently, a cDNA encoding the 2 subunit of the human brain sodium channel, SCN2B, was isolated and mapped by FISH on chromosome 11q23. 5 The voltagegated sodium channels are membrane proteins responsible for the initiation and propagation of action potentials in most excitable cells. In the rat brain, these channels are a heterotrimeric complex composed of a pore-forming α subunit and two smaller auxiliary subunits, 1 and 2.
6,7 Human 2 is a 186 amino acid glycoprotein with a short intracellular COOH-terminal domain, a single transmembrane segment, and a large extracellular domain containing a predicted immunoglobulin (Ig) V-type fold with a disulfide bond and four N-linked glycosylation sites. The human protein has 89% amino acid sequence identity and 93% similarity to the rat 2 and, accordingly, many of the structural properties are conserved. 5, 7 Based on homology between the rat 2 and the cell adhesion molecule contactin, it has been postulated that 2 might interact with proteins of the extracellular matrix during the myelination process of the central and the peripheral nervous systems as suggested by the presence of 2 in rat dorsal root ganglia. 5 Correspondingly, the human 2 has the highest similarity to another cell adhesion molecule, the myelin protein zero (p0), a major component of the peripheral myelin which contains an extracellular Ig loop between two cysteine residues and N-linked glycosylation sites. Mutations in myelin p0 cause an autosomal dominant form of demyelinating CMT diseases, CMT type 1B. 8 On the basis of the protein homologies, chromosomal localisation, and the postulated role during the myelination process, human SCN2B has been considered a potential candidate for CMT4B.
In the present study, we first characterised the genomic structure of the SCN2B gene and then demonstrated that SCN2B is not the CMT4B gene. A search for mutations in the coding region of SCN2B in CMT4B patients yielded negative results. In addition, a refined physical localisation showed that SCN2B maps approximately 20 cM distal to the critical region for the disease.
Materials and Methods

DNA Extraction
DNA was extracted from peripheral leukocytes of the CMT4B patients using standard methods. 9 DNA extraction from positive YAC clones was performed as described elsewhere. 10 
Genomic Structure of the SCN2B Gene and Mutation Analysis
PCR reactions on the SCN2B gene were performed according to standard protocols 9 using 500 ng of genomic DNA, 200 µM of each dNTP, 30 pmol of each primer, 1 or 1.5 mM of [Mg2 + ], and 1.25 U of Taq polymerase, in a final volume of 50 µl. The same PCR conditions with 1 mM of [Mg2 + ] were also used to amplify the four exons of the SCN2B gene in the CMT4B patients. The following couples of primers designed on the intron-exon boundaries were used ( Figure 1 and Table 1) : UTR-5' and EX1R for exon 1, with an annealing temperature of 55°C; EX2F and IR for exon 2, using an annealing temperature of 61°C; IF and IBR at annealing temperature of 59°C for exon 3; and finally, IBF2 and EBR3 for the last exon using an annealing temperature of 59°C.
Molecular cloning was carried out using the pCR II vector kit from Invitrogen following the manufacturer's instructions. Finally, cycle sequencing was performed using a PCR-dye primer and/or terminator protocol on an Applied Biosystem 373A Sequencer.
Physical Mapping
Physical mapping of the SCN2B gene was performed using the GenBridge 4 Radiation Hybrid panel 11 (Research Genetics, Huntsville, Alabama, USA) as well as the CEPH mega-YAC library (provided by the YAC screening Centre DIBIT, Milan, Italy).
Results and Discussion
Since only the 648 bp open reading frame (ORF) of the human SCN2B cDNA was available, we first characterised the SCN2B genomic structure. To this end, we designed two pairs of primers which were expected to amplify two overlapping fragments of an average size of 600 bp from human genomic DNA. This hypothesis was based on the homology to the highly conserved rat gene where two introns were identified in the coding sequence of the mature 2 protein. 7 Using the first pair of primers, EAFN and EAR ( Figure 1 and Table 1 ), located in the 5' portion of the cDNA, we were not able to obtain a single amplification product, probably because of the homology between this region of the gene and molecules belonging to the Ig superfamily. On the other hand, primers EBF and EBR ( Figure 1 and Table 1 ) from the 3' portion of the coding sequence amplified a fragment of approximately 1.5 Kb which was cloned in the pCR II vector (Invitrogen Corporation, Carlsbad, California, CA, USA). The recombinant clones were entirely sequenced and an intron of 977 bp was identified.
In order to obtain a single amplification product containing the 5' portion of the gene using SCN2B t specific primer sequences, we extended the sequence of the cDNA to its untranslated regions. We performed a BLAST search of sequences similar to the human SCN2B coding sequence on the Expressed Sequence Tag human cDNA database (http://www.ncbi.nih.gov/ dbEST/index.html. We retrieved EST clones with high homology to SCN2B and belonging to the same contig (THC 168161, TIGR database) and we partially sequenced two of them (IMAGE Consortium Clones ID = 25456 and ID = c-0cd03) which were expected to contain the untranslated regions of SCN2B. The sequence of 190 nt from the 5'-UTR and 236 nt from the 3'-UTR was determined and is shown in Figure 1 . Several forward primers were then designed from the 5'-UTR as well as the 5' end of the cDNA and used in combination with various reverse primers from the 3' end of the coding sequence. Only the pair of primers EAFN2 and EBFR ( Figure 1 and Table 1 ) were able to amplify a product of approximately 450 bp which was cloned in pCR II. The recombinant clones were sequenced and an additional intron of 289 bp was found.
Because a PCR product had been obtained using primers UTR-5' with INTR and EAFN3 with IR ( Figure 1 and Table 1 ), whereas no PCR product had been obtained using these primers in different combinations, we deduced that a large intron had to be present between primers INTR and EAFN3. In order to amplify this last intron, we screened by PCR the pools from a human CEPH Mega-YAC library using EAFN2/EBFR as primers and we found three positive YAC clones (665E10, 742F9, and 785E12). Clone 665E10 was used as a template in a long PCR reaction (Boehringer, Mannheim Corporation, Indianapolis, IN, USA) using primers EAFN and IR ( Figure 1 and Table 1 ). A PCR product of more than 9 Kb was identified and cloned in pCR II. Only the intron-exon boundaries of an intron of approximately 9 Kb were sequenced as shown in Figure 1 . This intron, located in the sequence coding for the cleaved signal peptide of SCN2B, was not identified in previous work on the rat gene. 7 Using primers designed on the intron-exon boundaries already established, we amplified the other two introns of 289 and 977 bp from the same YAC clone 665-E-10, thus confirming the results obtained starting from genomic DNA.
The established exon-intron structure of the SCN2B gene is schematically illustrated in Figure 2 . Based on this gene structure, we searched for mutations in the SCN2B genes of our CMT4B patient sample consisting of five affected individuals from the inbred Italian pedigree used to map the CMT4B gene (1945, 273, 279, 287, and 1943 from the pedigree reported in reference 4), two affected sibs born from unaffected parents and one sporadic CMT4B case. 12 We amplified the 4 exons of the SCN2B gene using primers designed for the intron boundaries. Only the wild-type allele was found in all patients by analysis of the entire coding sequence of each gene.
At the same time, we performed a refined physical localisation of the SCN2B gene to confirm its previous location by FISH on chromosome 11q23. A search in the CEPH YAC contig map of the human genome 13 allowed us to assign the positive clones, retrieved through PCR screening of the CEPH YAC library, to two clusters of clones recognised by Généthon's markers D11S1340, D11S939, and D11S1356. These markers are located 20 cM distal to the critical interval for Exclusion of the SCN2B gene as candidate for CMT4B A Bolino et al t CMT4B, which is delimited by markers D11S1332 and D11S917 located in 11q22.1, as determined from the same YAC contig map. To confirm these results which excluded the SCN2B gene from the region of interest, we screened by PCR a panel of radiation hybrids using EBF/EBR as primers ( Figure 1 and Table 1 ). Thus, the SCN2B gene was mapped on chromosome 11q23 at 1.92 cR from the STS marker WI-7642 of the integrated map from the Whitehead Institute (http://www-genome.wi.mit.edu/). This STS is flanked by Généthon's markers D11S1340 proximally and D11S936 distally, which are located 20 cM distal to the lower limit of the CMT4B region. We therefore concluded that SCN2B is not the CMT4B gene. To our knowledge, no other disease has been mapped to the 11q23 region for which SCN2B might constitute a suitable candidate gene.
